UBS lifts Visa target to $420; Basilea gains $30 million BARDA grant

UBS raised its 2025/26 price target for Visa Inc. to USD 420 per share and kept a Buy rating, according to analyst Timothy Chiodo’s study released on 29 July 2026.

Swiss biotech Basilea Pharmaceutica announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) approved an additional USD 30 million for the Phase‑III development of its antifungal candidate Fosmanogepix. The new funding brings total BARDA support for Fosmanogepix and BAL2062 to USD 123 million, with the agreement allowing up to USD 268 million over twelve years. Basilea shares rose about 1.9% to CHF 52.80 on the SIX exchange following the news.